4.8 Pharmacotherapy of ADHD Flashcards

1
Q

What increases someone’s chance for having ADHD?

A

Higher rate if a first-degree relative like a parent has ADHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Is the etiology of ADHD multifactoral?

A

Yes (environmental, genetics, physiological)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How many children w ADHD will get diagnosed in adulthood?

A

1/3 of children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

There is an increased risk of what if ADHD is left untreated?

A

Increased risk of substance use and antisocial personality disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the diagnostic criteria of ADHD?

A
  • For each sx domain, must have at least 6 sxs present
  • For older adolescents and adults (17 and older), at least 5 sxs are required for either of two specifiers
  • Several inattentive or hyperactive sxs must be present prior to age 12
  • Several inattentive or hyperactive impulse sxs are present in 2 or more settings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the sxs of the inattention domain?

A
  • Fails to give close attention to details, makes careless mistakes
  • Difficulty sustaining attention in tasks or play activities
  • Doesn’t seem to listen when spoken to directly
  • Doesn’t follow through on instructions, fails to finish hw, chores, duties in workplace
  • Difficulty organizing tasks and activities
  • Avoids, dislikes, reluctant to engage in tasks that require sustained mental effort
  • Loses things necessary for tasks
  • Easily distracted by extraneous stimuli
  • Forgetful in daily activities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the sxs of the hyperactivity and impulsivity domain?

A
  • Fidgets w or taps hands/feet, squirms in seat
  • Leaves seat in situations when remaining seated is expected
  • Runs about or climbs in inappropriate situations
  • Unable to play or engage in leisure activities quietly
  • Hyperactivity
  • Talks excessively
  • Blurts out answer before question is completed
  • Difficulty waiting their turn
  • Interrupts or intrudes on others
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How fast are dose response effects seen w stimulants?

A

Short period of time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are stimulant dosing considerations for pediatric pts?

A

Calculating a dose in pediatric pts based on mg/kg not found to be helpful as variations in dosing not found to be due to height or weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What stimulant dosage formulation is preferred for pts weighing <16 kg?

A

IR preferred due to limited low-dose availability of long-acting stimulants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When should stimulant be given for ADHD?

A

Avoid giving dose too late in the day, may give an after-school dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What requires longer-acting formulations?

A

Late afternoon sxs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Can a pt use two different stimulants?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Can a pt use two different dosage forms of the same stimulant?

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is special consideration for mydayis (mixed amphetamine salts)?

A

Max dose 25 mg/day (adults) or 12.5 mg (age 13-17) if CrCl <30-15 ml/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are special considerations for daytrana (methylphenidate)?

A
  • Apply patch to outside of hip 2 hrs prior to needed effects, remove after 9 hrs (alternate hip daily)
  • Reserved for those who respond to methylphenidate and would benefit from patch
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are special considerations for vyvanse (lisdexamfetamine)?

A
  • Prodrug covalently linked to 1-lysine; converted to dextroamphetamine via 1st pass/hepatic metabolism
  • All dosage forms MUST be swallowed whole
  • Not useful in no response to dextromethorphan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are special considerations for jornay AM (methylphenidate hydrochloride)?

A
  • Take dose in evening between 6:30 and 9:30pm
  • Must start w titration for dosing, do not switch mg per mg if pt already on IR methylphenidate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are AEs of stimulants?

A
  • Appetite loss
  • Abdominal pain
  • Headaches
  • Sleep disturbances
  • Decreased growth
  • Hallucinations or other psychotic scs (rare)
  • Increased BP (1-4 mmHg)
  • Increased HR (1-2 bpm)
  • Sudden cardiac death (rare)
  • Priapism
  • Peripheral vasculopathy (Reynaud’s)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the management of reduced appetite/ weight loss of stimulants?

A

High calorie meal when stimulant effects are low (breakfast, dinner)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the management of stomach ache of stimulants?

A

Give on full stomach, lower dose if possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the management of insomnia of stimulants?

A

Dose earlier in day, lower last dose of day or give earlier, consider sedating med at bedtime

23
Q

What is the management of rebound sxs of stimulants?

A

Longer acting stimulant trial, atomoxetine, antidepressant

24
Q

What is the management of irritability, jitteriness of stimulants?

A

Assess for co-morbid conditions, reduce dose, consider mood stabilizer, or atypical antipsychotic

25
Q

What is the management of hallucinations of stimulants?

A

D/c stimulant, reassess diagnosis

26
Q

What is the management of sudden cardiac death risk of stimulants?

A
  • Risk no greater in clinical trials than general population - assess risk of cardiac structural abnormality and family hx
  • If concern, cardiac ECHO
27
Q

What are the monitoring parameters of stimulants?

A
  • Appetite
  • Behavior
  • BP
  • Growth rate (height/weight)
  • HR
  • Sleep
  • ECG may be considered based on cardiac risk
28
Q

Which drugs are alpha 2 agonists?

A
  • Intuniv (guanfacine ER)
  • Kapvay (clonidine ER)
29
Q

What substrate is intuniv (guanfacine ER)?

A

3A4 substrate

30
Q

What must be done if pt wanted to d/c alpha 2 agonists?

A

Must be tapered if d/c to avoid rebound HTN

31
Q

Which drugs are NE reuptake inhibitors?

A
  • Atomoxetine (strattera)
  • Viloxazine (Qelbree)
32
Q

What substrate is atomoxetine (strattera)?

A

2D6

33
Q

What is dosing of atomoxetine (strattera) based on?

A

Weight based dosing

34
Q

How must viloxazine (qelbree) be taken?

A

Swallow capsules whole or put in applesauce

35
Q

What substrate is viloxazine (qelbree)?

A

2D6/UGT substrate

36
Q

What inhibitor is viloxazine (qelbree)?

A

Strong 1A2 inhibitor

37
Q

What are AEs of atomoxetine and viloxazine?

A
  • Increased HR and BP
  • increase in suicidal thinking (boxed warning)
38
Q

What are AEs of clonidine and guanfacine?

A
  • Decreased HR and BP, orthostasis
  • Somnolence
  • Dizziness
  • Rebound HTN if abrupt d/c
39
Q

What are monitoring parameters of non-stimulants?

A
  • Appetite
  • Behavior
  • BP
  • Growth rate (height, weight): atomoxetine
  • HR
  • LFTs (atomoxetine)
  • Sleep
40
Q

Is bupropion FDA approved for ADHD?

A

No

41
Q

What inhibitor is bupropion?

A

2D6

42
Q

What is bupropion CI in?

A

CI in seizure disorders and eating disorders

43
Q

Is TCA more effective than methylphenidate?

A

No

44
Q

What is a big concern w TCAs?

A

Cardiac concerns - sudden cardiac death in children, lethal in overdose

45
Q

When would atypical antipsychotics be useful in a pt w ADHD?

A

May be useful if there is comorbid bipolar disorder, conduct disorder, intermittent explosive disorder

46
Q

Can atypical antipsychotics be used as monotherapy for ADHD?

A

No

47
Q

What are the AAP tx guidelines for preschool age pts?

A
  • 1st line: parent training in behavior management (PTBM)
  • 2nd line: PTMB + FDA approved med
48
Q

What are the AAP tx guidelines for elementary and middle school age?

A

1st line: FDA approved med + PTBM

49
Q

What are the AAP tx guidelines for adolescents (age 12-18)?

A

1st line: FDA approved med, may offer PTBM

50
Q

What are the APP med recommendations for preschool age pts?

A
  • 1st line: methylphenidate
  • Non stimulant meds are not FDA approved for this age group
51
Q

What are the APP med recommendations for elementary/middle school/adolescent pts?

A
  • 1st line: stimulants
  • 2nd line: atomoxetine, guanfacine ER, clonidine ER
52
Q

What are the APP med adjunctive tx recommendations?

A
  • May be considered if stimulant is not fully effective or limited by SEs
  • Only guanfacine ER and clonidine ER have evidence as adjuncts to stims
53
Q

What does the NICE: ADHD 2018 guidelines for adults recommend?

A
  • Methylphenidate (short or LA) OR lisdexamfetamine [if no response, switch]
  • Dextroamphetamine (if unable to tolerate lisdexamfetamine long half life)
  • Atomoxetine (if no sx response to above agents)